PYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64mood

MRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodMRVL−0.26moodESTC+0.60moodBNTX−0.73moodAFRM+0.59moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10mood

RBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodRBRK−0.33moodTM−0.05moodASML−0.04moodDKNG+0.64moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47mood

GLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodGLCNF−0.50moodT+0.32moodPLTR+0.45moodBAC−0.10moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31mood

GE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodGE+0.75moodULTA−0.04moodAER+0.35moodBWLP+0.47moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04mood

MELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodMELI+0.42moodWDAY+0.62moodFLUT+0.59moodADSK+0.31moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88mood

ETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodETN+0.55moodNWFL+0.45moodCTVA+0.35moodASMLF−0.04moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35mood

PD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPD+0.43moodBX−0.35moodGAP+0.69moodFTNT+0.88moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08mood

COST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44moodCOST+0.35moodMSFT+0.49moodCYTK−0.72moodUUUU+0.35moodJNJ+0.58moodJOBY+0.08moodS−0.40moodAPP+0.08moodPYPL−0.34moodIREN−0.46moodFRO+0.73moodCVX+0.44mood

StockSays

GLMD

← Markets

GLMDGalmed Pharmaceuticals Ltd.

Discussion

Nothing said here yet.

to join the conversation.

—

Thu, Jul 16
9:05 AMinvestorshub.advfn.comGalmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)
Mon, Jun 22
6:00 AMYahooGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
Mon, Jun 8
6:00 AMYahooGalmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Wed, May 6
6:30 AMYahooTissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

GLMD · Galmed Pharmaceuticals Ltd. — sentiment, insiders, filings